Abbott’s spinal cord stimulator approved for diabetic peripheral neuropathy use

The FDA extended its approval for Abbot’s Proclaim XR spinal cord stimulator.

Advertisement

Proclaim is now approved for patients with painful diabetic peripheral neuropathy, Abbott said in a Jan. 26 news release. The SCS system also connects to the Abbott’s NeuroSphere virtual clinic, which allows for remote communication with physicians.

Abbott’s Proclaim SCS was approved for chronic pain treatment in 2019.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.